Keyword: Olivier Brandicourt
Eight months removed from handing the reins at Sanofi to Paul Hudson, Oliver Brandicourt is taking a board seat at RNAi therapy maker Alnylam.
Big Pharma CEOs have their own way of cozying up to the world’s second largest pharmaceutical market—by getting themselves Chinese names.
Sanofi CEO Olivier Brandicourt took the reins at a tough time for the drugmaker. Now, he's handing those reins to Novartis pharma chief Paul Hudson.
As spring rolls on each year, proxy filings pile up, disclosing executive pay for the prior year. And as in past years, FiercePharma has tracked the info to present the top CEO pay packages in biopharma, ranging from nearly $60 million in 2018 down to $16 million.
Sanofi has been among those hardest hit by diabetes pressure, and now, competition is hurting the prized asset from its $11.6 billion Bioverativ buy.
Sanofi is working on a succession plan for CEO Olivier Brandicourt, who'll hit mandatory retirement age in 2021.
Some Big Pharma CEOs got big pay raises last year despite problems at their companies. Sanofi chief Olivier Brandicourt wasn't one of them.
The move comes as Lilly and the other two big diabetes drugmakers face increasing political pressure on rising insulin prices.
Once the Senate finance committee’s drug pricing hearing started on Tuesday, it didn’t take long for sparks to fly.
